Cargando…

A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass

OBJECTIVE: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. MATERIALS AND METHODS: Prospective single-center...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Montoliu, Laura, Rodríguez-Peña, M-Mar, Puig, Rocío, Astiarraga, Brenno, Guerrero-Pérez, Fernando, Virgili, Nuria, López-Urdiales, Rafael, Osorio, Javier, Monseny, Rosa, Lazzara, Claudio, Sobrino, Lucía, Pérez-Maraver, Manuel, Pérez-Prieto, María, Pellitero, Silvia, Fernández-Veledo, Sonia, Vendrell, Joan, Vilarrasa, Nuria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616869/
https://www.ncbi.nlm.nih.gov/pubmed/37916149
http://dx.doi.org/10.3389/fendo.2023.1181744
Descripción
Sumario:OBJECTIVE: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. MATERIALS AND METHODS: Prospective single-center non-randomized controlled study, including patients with class II-III obesity and T2D undergoing mRYGB. At baseline and one year after surgery we performed body composition measurements, biochemical analysis, a meal tolerance test (MTT) and lipid test (LT) with determination of the area under the curve (AUC) for insulin, C-peptide, GLP-1, GLP-2, and fasting determinations of succinate, zonulin, IL-6 and study of gut microbiota. RESULTS: Thirteen patients aged 52.6 ± 6.5 years, BMI 39.3 ± 1.4 kg/m(2), HbA(1c) 7.62 ± 1.5% were evaluated. After mRYGB, zonulin decreased and an increase in AUC after MTT was observed for GLP-1 (pre 9371 ± 5973 vs post 15788 ± 8021 pM, P<0.05), GLP-2 (pre 732 ± 182 vs post 1190 ± 447 ng/ml, P<0.001) and C- peptide, as well as after LT. Species belonging to Streptococaceae, Akkermansiacea, Rickenellaceae, Sutterellaceae, Enterobacteriaceae, Oscillospiraceae, Veillonellaceae, Enterobacterales_uc, and Fusobacteriaceae families increased after intervention and correlated positively with AUC of GLP-1 and GLP-2, and negatively with glucose, HbA(1c), triglycerides and adiposity markers. Clostridium perfringens and Roseburia sp. 40_7 behaved similarly. In contrast, some species belonging to Lachnospiraceae, Erysipelotricaceae, and Rumnicocaceae families decreased and showed opposite correlations. Higher initial C-peptide was the only predictor for T2D remission, which was achieved in 69% of patients. CONCLUSIONS: Patients with obesity and T2D submitted to mRYGB show an enhanced incretin response, a reduced gut permeability and a metabolic improvement, associated with a specific microbiota signature.